Multiway
Development of a new multiplex technology adapted to Point of Care diagnosis
Case study
Multiway
Development of a new multiplex technology adapted to Point of Care diagnosis
Background
BIOASTER has received a grant from the Bill & Melinda Gates Foundation to develop high sensitive multiplex rapid diagnostic tests in collaboration with Global Access Diagnostics and Global Health Lab
Challenges
While Lateral Flow Assays (LFA) are highly valued as inexpensive, quick, and easy to use in developing countries, the technology has historically lacked the high sensitivity achieved with laboratory analytical reference methods.
BIOASTER will leverage its breakthrough Colicin/Immunity (COLPLEX) technology to develop, from feasibility to prototype readiness, a unique, low sample-volume, highly-sensitive multiplex reagent platform.
Solution
BIOASTER has harnessed the high-affinity interaction of specific bacterial proteins, the Colicin family and its counterparts, Immunity proteins, as a solid-phase immunoassay technology platform in which one binding partner is deployed as a tag and the other as a capture molecule, offering a much-needed alternative (or addition)
to the long-established avidin/biotin tag-capture system perfectly, adapted to point of care diagnosis.
The primary outcome of this project is to demonstrate the potential of the COLPLEX technology as a versatile tool for high sensitive, multiplex diagnostics, through the development of multiplex immunoassay and nucleic acid amplification LFA.
Results
The technical feasibility of the COLPLEX technology has been sucessfully demonstrated. A 3-plex lateral flow assay has been developed showing high senstivity and no cross-reactivity
Outlook
The COLPEX technology is perfectly adapated to several diagnostic applications that need high-performance multiplex rapid tests